Impact of the Major Candida glabrata Triazole Resistance Determinants on the Activity of the Novel Investigational Tetrazoles VT-1598 and VT-1161-Reference-Cited by-同舟云学术

Impact of the Major Candida glabrata Triazole Resistance Determinants on the Activity of the Novel Investigational Tetrazoles VT-1598 and VT-1161

Published:2019-10 Issue:10 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Nishimoto Andrew T.¹,Whaley Sarah G.¹^ORCID,Wiederhold Nathan P.²^ORCID,Zhang Qing¹,Yates Christopher M.³,Hoekstra William J.³,Schotzinger Robert J.³,Garvey Edward P.³,Rogers P. David¹

Affiliation:

1. University of Tennessee Health Science Center, Memphis, Tennessee, USA

2. University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA

3. Viamet Pharmaceuticals Inc., Durham, North Carolina, USA

Abstract

VT-1161 and VT-1598 are promising investigational tetrazole antifungals that have shown in vitro and in vivo activity against Candida and other fungi. Candida glabrata is a problematic opportunistic pathogen that is associated with high mortality in invasive infection, as well as both intrinsic and rapidly acquired antifungal resistance.

Funder

HHS | NIH | National Institute of Allergy and Infectious Diseases

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01304-19

Reference42 articles.

1. Changes in Prevalence of Health Care–Associated Infections in U.S. Hospitals

2. Changing trends in the epidemiology of Candida blood stream infections: A matter for concern?*

3. The PATH (Prospective Antifungal Therapy) Alliance® registry and invasive fungal infections: update 2012